- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Nerlynx (neratinib) / Puma
Enrollment closed, Enrollment change, Metastases: Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 21, 2016
P1/2, N=22, Active, not recruiting,
Recruiting --> Active, not recruiting | N=70 --> 22
- |||||||||| telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 17, 2016
P1, N=124, Active, not recruiting,
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Apr 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects (clinicaltrials.gov) - Feb 17, 2016
P2, N=43, Active, not recruiting,
Trial primary completion date: Dec 2015 --> Apr 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> May 2016
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Feb 17, 2016
P1/2, N=189, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> May 2016 Recruiting --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - Feb 13, 2016
P2, N=80, Active, not recruiting,
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Jun 2015
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 12, 2016
P1/2, N=150, Active, not recruiting,
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Study in Advanced Solid Tumors (clinicaltrials.gov) - Feb 11, 2016
P2, N=8, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Feb 10, 2016
P1/2, N=23, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=63 --> 23
- |||||||||| EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment closed, Trial primary completion date, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Feb 4, 2016
P1, N=30, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
- |||||||||| seribantumab (MM-121) / Elevation Oncology
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers (clinicaltrials.gov) - Feb 4, 2016
P1, N=48, Completed,
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Nov 2013
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Cetuximab Rechallenge Study (clinicaltrials.gov) - Feb 3, 2016
P2, N=35, Recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Nov 2013 Trial primary completion date: Apr 2016 --> Jun 2018
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Surgery, Metastases: Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=47, Active, not recruiting,
Trial primary completion date: Apr 2016 --> Jun 2018 Recruiting --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial initiation date, Trial primary completion date, Metastases: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 29, 2016
P2, N=25, Not yet recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Jun 2015 Initiation date: Sep 2015 --> Jul 2016 | Trial primary completion date: Jul 2017 --> Jul 2018
- |||||||||| E7820 / Eisai
Biomarker, Enrollment closed, Enrollment change, Trial initiation date, Trial primary completion date, Metastases: A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors (clinicaltrials.gov) - Jan 28, 2016
P2, N=41, Active, not recruiting,
Initiation date: Sep 2015 --> Jul 2016 | Trial primary completion date: Jul 2017 --> Jul 2018 Completed --> Active, not recruiting | N=99 --> 41 | Initiation date: Aug 2006 --> Sep 2007 | Trial primary completion date: May 2010 --> Dec 2009
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Study in Advanced Solid Tumors (clinicaltrials.gov) - Jan 26, 2016
P2, N=34, Completed,
Completed --> Active, not recruiting | N=99 --> 41 | Initiation date: Aug 2006 --> Sep 2007 | Trial primary completion date: May 2010 --> Dec 2009 Active, not recruiting --> Completed
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Enrollment open, Metastases: Regorafenib and Cetuximab in Patients With Advanced Malignancy (clinicaltrials.gov) - Jan 26, 2016
P1, N=83, Recruiting,
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Chemoradiation Treatment for Head and Neck Cancer (clinicaltrials.gov) - Jan 20, 2016
P2, N=60, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment open, Trial initiation date, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jan 19, 2016
P1, N=22, Recruiting,
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Aug 2015
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: A Phase Ib Trial of Concurrent Cetuximab (ERBITUX (clinicaltrials.gov) - Jan 17, 2016
P1, N=18, Recruiting,
Trial primary completion date: Aug 2014 --> Aug 2017 Trial primary completion date: Apr 2015 --> Dec 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Jan 17, 2016
P=N/A, N=40, Active, not recruiting,
Trial primary completion date: Apr 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Enrollment closed, Metastases: Regorafenib and Cetuximab in Patients With Advanced Malignancy (clinicaltrials.gov) - Jan 15, 2016
P1, N=83, Active, not recruiting,
Trial primary completion date: Apr 2016 --> Apr 2018 Recruiting --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, urelumab (BMS-663513) / BMS, Ono Pharma
Enrollment closed, Combination therapy, Metastases: Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jan 11, 2016
P1, N=104, Active, not recruiting,
N=115 --> 185 Recruiting --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, Enrollment closed, Trial primary completion date, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jan 11, 2016
P1/2, N=30, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed, Trial primary completion date, Metastases: ERBITUX (clinicaltrials.gov) - Jan 11, 2016
P2, N=40, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Sep 2017
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, motolimod (VTX 2337) / BMS
Biomarker, Enrollment change, Trial primary completion date, PD(L)-1 Biomarker: A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (clinicaltrials.gov) - Jan 7, 2016
P1, N=24, Recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Sep 2017 N=15 --> 24 | Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Study of Erbitux (clinicaltrials.gov) - Dec 22, 2015
P1, N=48, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Surgery, Metastases: Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 21, 2015
P1/2, N=47, Recruiting,
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Trial primary completion date, Combination therapy: Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) - Dec 21, 2015
P1, N=354, Active, not recruiting,
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed, Trial primary completion date, Metastases: Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 18, 2015
P2, N=75, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Nov 2015
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Dec 18, 2015
P2, N=256, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Nov 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2016
|
